Analyst Price Targets — XGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 24, 2026 8:25 pm | — | Roth Capital | $8.00 | $4.52 | TheFly | Exagen initiated with a Buy at Roth Capital |
| May 12, 2026 11:35 am | — | BTIG | $8.00 | $3.98 | TheFly | Exagen price target lowered to $8 from $9 at BTIG |
| April 20, 2026 1:10 pm | — | Canaccord Genuity | $8.00 | $2.97 | TheFly | Exagen price target lowered to $8 from $10 at Canaccord |
| March 11, 2026 1:15 pm | — | UBS | $10.00 | $3.11 | TheFly | Exagen price target lowered to $10 from $12 at Craig-Hallum |
| March 10, 2026 7:38 pm | Mark Massaro | BTIG | $9.00 | $3.25 | StreetInsider | Exagen (XGN) PT Lowered to $9 at BTIG |
| February 17, 2026 12:15 pm | Mark Massaro | BTIG | $10.00 | $3.28 | TheFly | Exagen price target lowered to $10 from $15 at BTIG |
| October 27, 2025 10:50 am | — | Canaccord Genuity | $15.00 | $11.96 | TheFly | Exagen price target raised to $15 from $11 at Canaccord |
| October 14, 2025 10:36 am | — | KeyBanc | $15.00 | $11.04 | TheFly | Exagen price target raised to $15 from $12 at KeyBanc |
| July 30, 2025 12:55 pm | — | Cantor Fitzgerald | $10.00 | $8.63 | TheFly | Exagen price target raised to $10 from $7 at Cantor Fitzgerald |
| July 29, 2025 11:28 pm | — | KeyBanc | $12.00 | $8.45 | TheFly | Exagen upgraded to Overweight from Sector Weight at KeyBanc |
Latest News for XGN
Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive diagnosis Performed consistently across more than 1,200 SLE patients and 14 medical centers, expanding on the original clinical validation CARLSBAD, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Exagen Inc.…
The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in Exagen (XGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Exagen NASDAQ: XGN reported record first-quarter revenue and reaffirmed its full-year outlook, as executives said growth in testing volume, improved reimbursement execution and expanding clinician adoption helped offset a weather-related disruption early in the quarter.
Exagen Inc. (XGN) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.2 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for XGN.
U.S. House Trading
No House trades found for XGN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.